The STING-CASM-GABARAP-LRRK2 pathway represents a novel mechanistic link between innate immune activation and LRRK2 kinase dysfunction in Parkinson's disease. This pathway reveals how lysosomal damage, microbial infection, and cellular stress converge to activate LRRK2, providing a unifying mechanism for various environmental triggers implicated in PD pathogenesis.
This mechanism is significant because LRRK2 mutations that increase kinase activity are among the most common genetic risk factors for familial and sporadic Parkinson's disease. Understanding the upstream activators of LRRK2 provides opportunities for therapeutic intervention at the earliest stages of pathogenesis.
¶ Historical Context and Discovery
The pathway was recently elucidated through research published in 2024 (PMID: 39812709), integrating findings from multiple fields:
- 2012-2018: Discovery of CASM (conjugation of ATG8 to single membranes) as a non-canonical autophagy process
- 2020-2022: Identification of GABARAP family proteins as key players in LRRK2 recruitment
- 2024: Demonstration that STING activation triggers CASM, leading to LRRK2 activation via GABARAP
This discovery bridges the fields of innate immunity (cGAS-STING pathway), autophagy (ATG8 family proteins), and LRRK2 biology in Parkinson's disease.
STING (Stimulator of Interferon Genes) is activated by multiple stimuli:
Direct STING agonists:
- DMXAA: A small molecule STING agonist
- cGAMP: The second messenger produced by cGAS
Stress-induced activation:
- LLOME (L-leucyl-L-leucine methyl ester): Lysosomal damage
- ML SA1: Lysosomal membrane permeabilization
- Nigericin: Ionophore causing lysosomal stress
Upon STING activation, the conjugation of ATG8 to single membranes (CASM) pathway is triggered:
Key components:
- ATG16L1: Essential for LC3/GABARAP lipidation on single membranes
- ATG12-ATG5 conjugate: Required for ATG8 family protein lipidation
- ATG3: E2-like enzyme facilitating conjugation
Process:
- STING translocation to the Golgi apparatus
- Recruitment of ATG16L1 to damaged lysosomes/endosomes
- Lipidation of ATG8 family proteins (LC3B, GABARAP, GABARAPL1, GABARAPL2)
- Formation of LC3/GABARAP-positive single-membrane structures
The critical discovery is that GABARAP specifically mediates LRRK2 recruitment and activation:
LIR (LC3-Interacting Region) motifs:
- Two predicted LIR motifs in LRRK2
- Direct interaction between GABARAP and LRRK2
- Other ATG8 family members cannot substitute for GABARAP
Recruitment steps:
- GABARAP lipidation via CASM
- LRRK2 recruitment to lysosomal membranes via GABARAP interaction
- LRRK2 kinase domain activation
- Phosphorylation of LRRK2 substrates (Rab proteins)
The requirement for CASM and GABARAP has been experimentally validated:
| Requirement |
Evidence |
| CASM required |
Blocked by ATG16L1 deletion |
| CASM required |
Blocked by Salip (ATG7 inhibitor) |
| CASM required |
Blocked by SopF (ATG4B inhibitor) |
| GABARAP required |
Other ATG8 members cannot substitute |
| TBK1/IKKε not required |
Kinase inhibitors do not block pathway |
The pathway provides a mechanistic explanation for how diverse stressors activate LRRK2:
flowchart TD
A["STING Activation"] --> B["CASM Induction"]
B --> C["GABARAP Lipidation"]
C --> D["GABARAP-LRRK2 Interaction"]
D --> E["LRRK2 Lysosomal Recruitment"]
E --> F["LRRK2 Kinase Activation"]
A1["DMXAA<br/>STING Agonist"] --> A
A2["LLOME<br/>Lysosome Damage"] --> A
A3["ML SA1<br/>Lysosomal Stress"] --> A
A4["Nigericin<br/>Ionophore"] --> A
A5["Mitochondrial<br/>DNA Release"] --> A
Lysosomal dysfunction:
- Lysosomal membrane permeabilization triggers CASM
- Relevant to Parkinson's disease where lysosomal dysfunction is prominent
- GBA mutations cause lysosomal dysfunction and increase PD risk
Mitochondrial dysfunction:
Microbial infection:
- Pathogen-associated molecular patterns activate STING
- Potential link to gut-brain axis in PD
The pathway is highly relevant to Parkinson's disease pathogenesis:
Genetic risk:
- LRRK2 G2019S mutation increases kinase activity
- Common in familial and sporadic PD
- The pathway explains how environmental factors may trigger LRRK2 activation in non-carriers
Pathological relevance:
- Lysosomal dysfunction is a hallmark of PD
- Mitochondrial dysfunction in substantia nigra
- Chronic neuroinflammation involving cGAS-STING
Therapeutic implications:
- Targeting upstream STING-CASM could prevent LRRK2 activation
- May be more effective than direct LRRK2 kinase inhibitors
- Could benefit both LRRK2 mutation carriers and sporadic patients
The pathway also explains LRRK2 activation in Crohn's disease:
- LRRK2 mutations increase Crohn's disease risk
- Gut inflammation activates STING
- Lysosomal damage in intestinal epithelial cells
- Potential for shared therapeutic approaches
The pathway intersects with alpha-synuclein pathology:
- α-Synuclein aggregation can cause lysosomal dysfunction
- May trigger CASM and secondary LRRK2 activation
- Creates feed-forward loop: LRRK2 → autophagy dysfunction → α-synuclein accumulation
PINK1-PARK2 mitophagy pathway intersects with CASM:
- Mitophagy involves ATG8 family proteins
- Mitochondrial damage triggers cGAS-STING
- Potential convergence on LRRK2 activation
The pathway is central to chronic neuroinflammation in PD:
- STING activation leads to type I interferon responses
- Creates pro-inflammatory milieu
- May explain IFN signature observed in PD brains
Multiple therapeutic strategies emerge from this pathway:
Direct STING inhibitors:
- H-151: Covalent STING antagonist
- C-176, C-178: STING inhibitors
- Would prevent CASM and subsequent LRRK2 activation
CASM inhibitors:
- Targeting ATG16L1
- ATG7 inhibition (Salip)
- ATG4B inhibition (SopF)
GABARAP-LRRK2 interface:
- Blocking LIR motif interactions
- Small molecule disruptors
Advantages over direct LRRK2 inhibitors:
- Addresses upstream activation
- May be beneficial for sporadic PD
- Broader therapeutic applicability
Pathway activation biomarkers could aid patient selection:
- Phospho-LRRK2 in CSF or blood
- GABARAP lipidation markers
- STING activation signatures
- Interferon-stimulated genes
¶ Key Proteins and Genes
| Protein/Gene |
Function |
Disease Link |
| STING (TMEM173) |
Innate immune sensor |
Triggers CASM |
| LRRK2 |
Leucine-rich repeat kinase |
Kinase activation in PD |
| GABARAP |
ATG8 family protein |
Recruits LRRK2 |
| ATG16L1 |
Autophagy protein |
Essential for CASM |
| ATG7 |
E1-like enzyme |
ATG8 lipidation |
| ATG5 |
Autophagy protein |
ATG8 lipidation |
| cGAS |
DNA sensor |
STING activation |
| TBK1 |
Kinase |
Traditional STING pathway |
The STING-CASM-GABARAP-LRRK2 pathway represents a paradigm-shifting mechanism that integrates innate immune activation with LRRK2 kinase dysregulation in Parkinson's disease. This pathway explains how diverse cellular stressors—including lysosomal damage, mitochondrial dysfunction, and microbial infection—converge to activate LRRK2 through a GABARAP-dependent mechanism.
The discovery of this pathway has important therapeutic implications:
- Provides new therapeutic targets upstream of LRRK2
- Suggests STING inhibitors may benefit PD patients
- Explains the link between lysosomal dysfunction and LRRK2 activation
- Provides a mechanistic basis for anti-inflammatory approaches in PD
Future research should focus on:
- Validating pathway activation in human PD brain tissue
- Developing brain-penetrant STING inhibitors
- Identifying biomarker signatures of pathway activation
- Testing therapeutic efficacy in preclinical models